CN100522949C - 哌嗪二酮类化合物 - Google Patents

哌嗪二酮类化合物 Download PDF

Info

Publication number
CN100522949C
CN100522949C CNB018125212A CN01812521A CN100522949C CN 100522949 C CN100522949 C CN 100522949C CN B018125212 A CNB018125212 A CN B018125212A CN 01812521 A CN01812521 A CN 01812521A CN 100522949 C CN100522949 C CN 100522949C
Authority
CN
China
Prior art keywords
compound
dione
methylene
piperazine
benzyloxypyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018125212A
Other languages
English (en)
Chinese (zh)
Other versions
CN1441789A (zh
Inventor
邓哲明
王惠珀
艾里克·I·C·李
李昂
顾记华
陈惠婷
范扬彬
陈雅兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
YIFA SCIENCE AND TECHNOLOGY Co Ltd
Original Assignee
YIFA SCIENCE AND TECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by YIFA SCIENCE AND TECHNOLOGY Co Ltd filed Critical YIFA SCIENCE AND TECHNOLOGY Co Ltd
Publication of CN1441789A publication Critical patent/CN1441789A/zh
Application granted granted Critical
Publication of CN100522949C publication Critical patent/CN100522949C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Devices For Conveying Motion By Means Of Endless Flexible Members (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
CNB018125212A 2000-05-09 2001-05-08 哌嗪二酮类化合物 Expired - Fee Related CN100522949C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30419100P 2000-05-09 2000-05-09
US60/304,191 2000-05-09

Publications (2)

Publication Number Publication Date
CN1441789A CN1441789A (zh) 2003-09-10
CN100522949C true CN100522949C (zh) 2009-08-05

Family

ID=23175471

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018125212A Expired - Fee Related CN100522949C (zh) 2000-05-09 2001-05-08 哌嗪二酮类化合物

Country Status (14)

Country Link
US (1) US6635649B2 (https=)
EP (1) EP1282609B1 (https=)
JP (1) JP5101781B2 (https=)
KR (1) KR100852965B1 (https=)
CN (1) CN100522949C (https=)
AT (1) ATE417614T1 (https=)
BR (1) BR0110745A (https=)
CZ (1) CZ301743B6 (https=)
DE (1) DE60137037D1 (https=)
HU (1) HUP0302358A3 (https=)
NO (1) NO326341B1 (https=)
RU (1) RU2269520C2 (https=)
WO (1) WO2001095858A2 (https=)
ZA (1) ZA200209917B (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288545B2 (en) * 2000-05-09 2007-10-30 Angiorx Corporation Piperazinedione compounds
CN100553636C (zh) 2000-08-04 2009-10-28 Dmi生物科学公司 二酮基哌嗪和包含它们的组合物的使用方法
US7935704B2 (en) * 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
WO2004030522A2 (en) * 2002-10-02 2004-04-15 Dmi Biosciences, Inc. Diagnosis and monitoring of diseases
EP2517718B1 (en) 2003-05-15 2016-03-02 Ampio Pharmaceuticals, Inc. Treatment of T-cell mediated diseases
CA2538352A1 (en) * 2003-09-25 2005-04-07 Dmi Biosciences Inc. Methods and products which utilize n-acyl-l-aspartic acid
AU2005212399B2 (en) * 2004-02-04 2011-09-22 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US8129527B2 (en) * 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
JP5856843B2 (ja) 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ，インコーポレイテッド ジケトピペラジンを用いた医薬組成物
CN102131775B (zh) * 2008-08-22 2015-12-16 不列颠哥伦比亚癌症局分支机构 雄激素受体n-末端活化的小分子抑制剂
CN102395581A (zh) * 2009-04-16 2012-03-28 泰立克公司 作为微管蛋白聚合抑制剂的取代的4-氨基-5-苯甲酰基-2-(苯基氨基)噻吩-3-腈和取代的4-氨基-5-苯甲酰基-2-(苯基氨基)噻吩-3-羧酰胺
EP2613786A4 (en) 2010-09-07 2013-10-23 Dmi Acquisition Corp TREATMENT OF DISEASES
US8710062B2 (en) * 2011-03-11 2014-04-29 Taipei Medical University Piperazinedione compounds
MY172699A (en) 2011-10-10 2019-12-10 Ampio Pharmaceuticals Inc Implantable medical devices with increased immune tolerance, and methods for making and implanting
EA028343B1 (ru) 2011-10-10 2017-11-30 Ампио Фармасьютикалз, Инк. Лечение дегенеративного заболевания сустава
EP2771007B1 (en) 2011-10-28 2018-04-04 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
BR112015020469A2 (pt) 2013-03-15 2020-01-28 Ampio Pharmaceuticals Inc Usos de da-dkp, composição e método para fornecimento de células-tronco a umindivíduo
JP6311097B2 (ja) * 2013-07-31 2018-04-18 学校法人東京薬科大学 微小管脱重合剤
RU2736513C2 (ru) 2014-08-18 2020-11-17 Ампио Фармасьютикалз, Инк. Лечение патологических состояний суставов
CN104356077B (zh) * 2014-09-11 2016-09-14 中国科学院南海海洋研究所 一类不对称酰基保护的2,5-二酮哌嗪衍生物及其制备方法和应用
SG11201707128TA (en) 2015-03-06 2017-09-28 Beyondspring Pharmaceuticals Inc Method of treating a brain tumor
AU2016229294B2 (en) 2015-03-06 2021-11-04 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
EP3310375A4 (en) 2015-06-22 2019-02-20 Ampio Pharmaceuticals, Inc. USE OF LOW-MOLECULAR FRACTIONS OF HUMAN SERUMALBUMINE IN THE TREATMENT OF ILLNESSES
JP6969848B2 (ja) 2015-07-13 2021-11-24 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド プリナブリン組成物
KR20180105685A (ko) 2016-02-08 2018-09-28 비욘드스프링 파마수티컬스, 인코포레이티드. 투카레솔 또는 이의 유사체를 함유하는 조성물
JP7025416B2 (ja) 2016-06-06 2022-02-24 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 好中球減少症を低減させるための組成物および方法
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
BR112019015974A2 (pt) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
CN109580801B (zh) * 2018-06-26 2021-09-07 深圳海王医药科技研究院有限公司 一种检测微管蛋白抑制剂及相关杂质的高效液相色谱法
CN112010930B (zh) * 2019-05-28 2022-08-02 首都医科大学 Rgd修饰的五环哌嗪二酮及其制备和应用
CA3215047A1 (en) 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors
CN117285516A (zh) * 2022-06-16 2023-12-26 大连万众益生大健康有限公司 脱氢苯基阿夕斯汀类化合物、其制备方法及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940709A (en) * 1984-11-02 1990-07-10 Fujisawa Pharmaceutical Co., Ltd. Piperazine compound as PAF-antagonist
US5708804A (en) * 1994-07-25 1998-01-13 International Business Machines Corp. Apparatus and method therefor of intelligently searching for information in a personal communications device
US5902812A (en) * 1994-02-14 1999-05-11 Xenova Limited Pharmaceutical piperazine compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5973574A (ja) * 1982-10-21 1984-04-25 Grelan Pharmaceut Co Ltd 環状ジペプチド類
GB8609908D0 (en) * 1986-04-23 1986-05-29 Fujisawa Pharmaceutical Co Piperazine compound
DK181687A (da) * 1986-04-23 1987-10-24 Fujisawa Pharmaceutical Co Piperazinderivater og fremgangsmaade til fremstiling deraf
GB9217331D0 (en) * 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
GB9402807D0 (en) * 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
JP3795093B2 (ja) * 1994-11-25 2006-07-12 キッセイ薬品工業株式会社 １−ヒドロキシインドール誘導体
JP3131574B2 (ja) * 1996-09-04 2001-02-05 新日本製鐵株式会社 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940709A (en) * 1984-11-02 1990-07-10 Fujisawa Pharmaceutical Co., Ltd. Piperazine compound as PAF-antagonist
US5902812A (en) * 1994-02-14 1999-05-11 Xenova Limited Pharmaceutical piperazine compounds
US5708804A (en) * 1994-07-25 1998-01-13 International Business Machines Corp. Apparatus and method therefor of intelligently searching for information in a personal communications device

Also Published As

Publication number Publication date
WO2001095858A2 (en) 2001-12-20
ZA200209917B (en) 2004-04-28
CZ20023693A3 (cs) 2003-05-14
ATE417614T1 (de) 2009-01-15
NO20025373L (no) 2002-12-13
NO326341B1 (no) 2008-11-10
JP5101781B2 (ja) 2012-12-19
KR20030005336A (ko) 2003-01-17
JP2004510701A (ja) 2004-04-08
WO2001095858A3 (en) 2002-03-21
DE60137037D1 (de) 2009-01-29
EP1282609A4 (en) 2003-06-04
BR0110745A (pt) 2003-12-30
HUP0302358A2 (hu) 2003-11-28
HUP0302358A3 (en) 2007-09-28
CN1441789A (zh) 2003-09-10
CZ301743B6 (cs) 2010-06-09
EP1282609B1 (en) 2008-12-17
EP1282609A2 (en) 2003-02-12
NO20025373D0 (no) 2002-11-08
US20020028819A1 (en) 2002-03-07
KR100852965B1 (ko) 2008-08-19
RU2269520C2 (ru) 2006-02-10
US6635649B2 (en) 2003-10-21

Similar Documents

Publication Publication Date Title
CN100522949C (zh) 哌嗪二酮类化合物
US8119683B2 (en) Aryl substituted sulfonamide compounds and their use as anticancer agents
US12090149B2 (en) SMAD3 inhibitors
KR20010014215A (ko) 항전이활성을 갖는 비스-인돌 유도체, 그의 제조방법 및그를 함유하는 약제학적 조성물
EP1741714B1 (en) Heterocyclic compound and anti-malignant-tumor agent containing the same as active ingredient
US11834432B2 (en) Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof
US8710062B2 (en) Piperazinedione compounds
AU2001294505B2 (en) Piperazinedione compounds
CA2408649C (en) Piperazinedione compounds
AU2001294505A1 (en) Piperazinedione compounds
CN115381815B (zh) 独脚金内酯衍生物在制备线粒体自噬抑制剂中的应用
JP2023180347A (ja) ハイブリッド型化合物又はその塩
JP2005507893A (ja) ２０（ｓ）−カンプトテシンの薬学的に許容可能な塩
EP1270008B1 (en) Fused tricyclic analogues of guanosine for treating tumors
CN120192318A (zh) 吡咯里嗪并[2,3-c]喹啉衍生物、合成方法及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090805

Termination date: 20120508